← Back to Dashboard

Sirolimus

IL-2-dependent T-cell proliferation inhibitor

2D Structure

Loading structure...

3D Structure

Loading 3D structure...

Chemical Identifiers

CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=…
QFJCIRLUMZQUOT-HPLJOQBZSA-N
ClinicalTrials.govPubMed

Clinical Development by Virus11

Hepacivirus C
HCV
Target: Human PTK
Phase 2
Preclinical
Phase 2
Phase 3
Approved
NCT01469884
Human betaherpesvirus 5
CMV
Target: Human PTK
Preclinical
Preclinical
Phase 2
Phase 3
Approved
NCT02683291
Influenza A virus
FLUAV
Target: Human PTK
Preclinical
Preclinical
Phase 2
Phase 3
Approved
NCT03901001
Human immunodeficiency virus 1
HIV-1
Target: Human PTK
Preclinical
Preclinical
Phase 2
Phase 3
Approved
NCT02990312
Human gammaherpesvirus 8
KSHV
Target: Human PTK
Phase 2
Preclinical
Phase 2
Phase 3
Approved
NCT01412515
Phase 2
Preclinical
Phase 2
Phase 3
Approved
NCT04461340
Rift Valley fever phlebovirus
RVFV
Target: Human PTK
Preclinical
Preclinical
Phase 2
Phase 3
Approved
PMID:28442428
Rubivirus rubellae
RuV
Target: Human PTK
Preclinical
Preclinical
Phase 2
Phase 3
Approved
PMID:28475412
Hepatitis B virus
HBV
Target: Human PTK
Preclinical
Preclinical
Phase 2
Phase 3
Approved
PMID:29730285
Hepatitis delta virus
HDV
Target: Human PTK
Preclinical
Preclinical
Phase 2
Phase 3
Approved
PMID:29730285
Preclinical
Preclinical
Phase 2
Phase 3
Approved
PMID:25487801